Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Etelcalcetide (Parsabiv) on Serum Calcification Propensity in Hemodialysis Patients
2018-000421-31Phase 2Completed
- Sponsor
- Ordensklinikum Linz
- Start
- Oct 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of etelcalcetide in end-stage kidney disease (ESKD) and secondary hyperparathyroidism (SHPT), sponsored by Ordensklinikum Linz. Primary endpoint: Change in T50 value. Started Oct 2018; status: completed.
02
Drugs
etelcalcetide
03
Conditions
end-stage kidney disease (ESKD)secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on 2018-000421-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000421-31.